4.4 Article

Autoimmunity and the risk of myeloproliferative neoplasms

Journal

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 95, Issue 7, Pages 1216-1220

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2009.020412

Keywords

myeloproliferative neoplasms; autoimmune diseases; polycythemia vera. essential thrombocythema; primary myelofibrosis; Crohn's disease; immune thrombocytopenic purpura; giant cell arteritis; polymyalgia rheumatica; aplastic anemia

Categories

Funding

  1. NIH
  2. National Cancer Institute
  3. Swedish Cancer Society
  4. Stockholm County Council
  5. Karolinska Institutet Foundations
  6. Shire Pharmaceuticals

Ask authors/readers for more resources

The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of myeloproliferative neoplasm. We found a prior history of any autoimmune disease to be associated with a significantly increased risk of myeloproliferative neoplasms (odds ratio (OR)=1.2; 95% confidence interval (CI) 1.0-1.3; P=0.021). Specifically, we found an increased risk of MPNs associated with a prior immune thrombocytopenic purpura (2.9; 1.7-7.2), Crohn's disease (1.8; 1.1-3.0), polymyalgia rheumatica (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter's syndrome (15.9; 1.8-142) and aplastic anemia (7.8; 3.7-16.7). The risk of myeloproliferative neoplasms associated with prior autoimmune diseases is modest but statistically significant. Future studies are needed to unravel the effects of these autoimmune diseases themselves, their treatment, or common genetic susceptibility.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available